Compare Amylx Pharmaceuticals Inc (AMLX) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Star Bulk Carriers Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Star Bulk Carriers Corp trades at $26.35 (market cap $2.94B). The key difference: Star Bulk Carriers Corp is the larger of the two by market cap, and Star Bulk Carriers Corp pays a 3.91% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SBLK | |
|---|---|---|
Market Cap | $1.98B | $2.94B |
Sector | Health | Industrials |
52-Week High | $18.70 | $28.21 |
52-Week Low | $7.64 | $16.79 |
Enterprise Value | $1.70B | $3.64B |
Dividend Yield | — | 3.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Star Bulk Carriers (SBLK) trades at $26.35, up 1.82% today, with a neutral technical signal and bullish moving averages. The company reported strong Q1 2026 earnings of $0.56 per share, beating estimates, and maintains a dividend payout. Revenue grew to $1.1 billion in 2026, with net income margin improving to 13.01%. Analyst consensus is bullish with 14 buy ratings.
SBLK presents a positive outlook with earnings beats and dividend returns, but faces risks from dry bulk market volatility and economic cycles. The stock's valuation at a P/E of 21.08 is reasonable given growth, yet investor caution is warranted on global trade fluctuations impacting shipping demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
